Patients with classic adrenal hyperplasia (CAH) may be able to reduce their glucocorticoid (GC) doses with crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, according to two studies recently published in The Journal of Clinical Endocrinology & Metabolism. Neurocrine Biosciences, Inc. funded the studies, and the company is marketing crinecerfont as CRENESSITY®. The two papers […]
